ThePharmYard > Raltegravir: first in class HIV integrase inhibitor

Click here to see all DOVE Medical Press titles in ThePharmYard

Pay-as-you-go medical and pharmaceutical industry information

About Us | Contact Us | Terms

Managed by NetworkPharma

The Publishers // Dove Medical Press

Raltegravir: first in class HIV integrase inhibitor

This expert article was written by Zelalem Temesgen and Dawd S Siraj and first published in Therapeutics and Clinical Risk Management, Volume 4, Number 2, April 2008

Product Details - See below for further product information
Note the document you buy is licensed for your own use only.

File type and size: PDF 0.084 MB
Publication size: 8 pages
Publication date: April 2008
Published by: Dove Medical Press
ThePharmYard product code: dove535

Our Price: £20.00
You are buying an e-document. This is a digital product and therefore UK VAT @ 17.50 % will be added at Checkout if your billing address is in the EU.

Related Products:

Combating HIV resistance - focus on darunavir

Raltegravir - an integrase inhibitor for antiretroviral therapy in HIV-1 infection

Further Product Information

AUTHORS:

Zelalem Temesgen¹
Dawd S Siraj²

¹Mayo Clinic, Rochester, MN, USA
²East Carolina University Greenville, NC, USA

ABSTRACT

On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment na�ve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.

ABOUT THE JOURNAL

Therapeutics and Clinical Risk Management

ISSN 1176-6336

An international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines.

Strategic Medcomms Forum 2010:
Reshaping the healthcare conversation

30 September 2010

Oxford University Museum of Natural History, Oxford, UK

Learn more here

What we do

ThePharmYard sells information relevant to the medical and pharmaceutical industries, on behalf of independent publishers, in the form of e-documents. Buy online now and access the information immediately.

If you have any problems or questions or comments of any sort, then do please contact us directly.

All transactions conducted independently by WorldPay

basket

checkout

terms

Browse all publications in ThePharmYard from DOVE Medical Press.

More about DOVE Medical Press

DOVE Medical Press is an international publisher of high-quality, peer-reviewed journals in the medico-scientific field. These journals focus on drug development and therapeutics with a particular interest in the patient perspective, compliance, health literacy, risk management programs, education, and communication. The evidence and opinion behind new and existing therapies are explored through comprehensive reviews, original research, and opinion. In addition, a promotional article monitoring (PAM) service for pharmaceutical executives is provided. Dove Medical Press has extensive experience in communications strategy and publication management and will respond rapidly and effectively to meet your requirements.

For more information about DOVE Medical Press please visit their own web site.

Selected Special Offers

1. Venlafaxine in Depression (in Primary Care)

2. Tiotropium in COPD (in Primary Care)

3. Pravastatin in Lipid Disorders (in Primary Care)

4. Escitalopram in Depression (in Primary Care)

5. Nicorandil in Angina (in Primary Care)

Our Best Sellers

1. An overview of CME/CPD credit systems around the world

2. Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications

3. Stepping up to Medical Sales Success - 2nd Edition

4. Quid Pro Quo Deals

5. Bipolar disorder - Disease overview

6. Bipolar disorder - Improving Practice (UK)

7. Olanzapine in bipolar disorder - Drug review

8. Developing Win-Win Key Opinion Leader Relationships

9. Levocetirizine in Allergic Rhinitis (in Primary Care)

10. Customer-Driven Positioning: The next generation approach to pharmaceutical product positioning

Latest Additions

1. Future of European Pharmaceutical Distribution

2. Global Dental Implants Market (2010 -2015)

3. Discretion is the better part of value: Five research-based rules for ensuring that strategy implementers implement

4. The competitive environment and hospital performance: An empirical investigation

5. Antecedents, environmental moderators and consequences of market orientation: A study of pharmaceutical firms in Ghana

Need help?

If you can't find what you are looking for, or have any problems or questions or comments at all, then please contact us directly.

If you are an Author or Publisher and have one or more publications you would like to make available to our specialist medical and pharmaceutical industry audience, then please contact us directly.

If you run your own web site and want to earn money from our affiliate scheme then please contact us directly.

Affiliates | About Us | Contact Us | Terms

ThePharmYard is an initiative for the international medical and pharmaceutical industries from NetworkPharma Ltd. Copyright 2010

Other services managed by NetworkPharma: [www.EuropeanCMEforum.eu] [www.KeywordPharma.com] [www.MedCommsForum.com] [www.MedCommsNetworking.co.uk] [www.NetworkPharma.tv] [www.ThePublicationPlan.com]

We accept the following credit and debit cards: amex visa visa_delta visa_electron mastercard switch jcb solo